Neoadjuvant Dose-dense Chemotherapy for HR+/HER2- Breast Cancer Patients With High Proliferation Index
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: dose-dense nab-paclitaxel followed by EC
Sponsor: Shantou Central Hospital